Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3Kd inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.…
Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in London
Pharming Group (NASDAQ: PHAR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 407 employees.
The shares were at 11.54 USD on 20 November 2026, down 26.9% over 52 weeks. Its 52-week range is 9.110 USD to 21.34 USD: the price is 45.9% below the high and 26.7% above the low.
At a market capitalisation of 816.78M USD, it trades at 36.1 times trailing earnings and 64.1 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, so PHAR is valued in line with them.
Pharming Group reports return on equity of 1.0%, an operating margin of 12.8% and revenue up 20.8% year over year.
It holds more cash than debt, a net cash position of 75.05M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 4 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 35.70 USD is 209.4% above the current price.